問卷

TPIDB > Search Result

Search Result

篩選

Study Statistics

5316Cases

20022027

Total

5316

  • I

    573

  • I/II

    251

  • II

    1225

  • II/III

    138

  • III

    2607

  • IV

    105

  • Others

    356

List

5316Cases

2022-10-01 - 2026-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites

2022-10-05 - 2024-02-12

Phase III

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-09-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-10-31 - 2026-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
  • Condition/Disease

    Sacroiliac Joint Pain

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
14Sites

Recruiting14Sites